Nuvation Bio raises $287.5M in convertible notes after greenshoe exercise

Filed July 6, 2026 · Period ending June 30, 2026 · ~1 min read

Key Changes

• high

  Underwriters exercised full over-allotment option for additional $37.5M in 0.75% convertible senior notes due 2032, bringing total offering to $287.5M with net proceeds of approximately $277.6M after fees.

  Exhibit 99.1 verify on EDGAR →
• medium

  Company entered into additional capped call transactions with cap price of $10.4580 per share (80% premium over June 25 stock price) to reduce potential dilution from note conversions, costing approximately $2.2M.

  Item 1.01 verify on EDGAR →
• medium

  Remaining greenshoe proceeds will fund general corporate purposes including working capital, operating expenses, capital expenditures, and administrative expenses.

  Exhibit 99.1 verify on EDGAR →